|Title:||Molecular-targeted Therapy for Chemotherapy-refractory Gastric Cancer: A Case Report and Literature Review||Authors:||Kuo, Hung-Yang
|Keywords:||Gastric cancer;trastuzumab;chemotherapy;refractory;ramucirimab;targeted therapy||Issue Date:||2014||Journal Volume:||34||Journal Issue:||7||Start page/Pages:||3695-3699||Source:||Anticancer Res.||Abstract:||
The prognosis of advanced gastric cancer (AGC) remains poor despite therapeutic advances in recent decades. Several recent positive phase III trials established the efficacy of second-line chemotherapy for metastatic gastric cancer in prolonging overall survival. However, malnutrition and poor performance of AGC in late stages usually preclude such patients from intensive treatment. Many targeted-therapies failed to show a significant survival benefit in AGC, but have regained attention after the positive result of ramucirumab was announced last year. Among all targeted agents, only trastuzumab, a monoclonal antibody against Human epidermal growth factor receptor-2 (HER2) protein, has been proven as having survival benefit by addition to first-line chemotherapy. Herein we reported a patient who benefited from adding trastuzumab to the same second-line combination chemotherapy (paclitaxel, 5-fluorouracil, and leucovorin) upon progression of bulky liver metastases. At least five months of progression-free survival were achieved without any additional toxicity. We also reviewed literature of molecularly-targeted therapy for chemotherapy-refractory gastric cancer, including several large phase III trials (REGARD, GRANITE-1, EXPAND, and REAL-3) published in 2013-2014.
|Appears in Collections:||腫瘤醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.